Until now, three PRMT5 inhibitors (GSK3326595, JNJ-64619178 and PF-06939999) are being used in six clinical trials (NCT02783300, NCT03573310, NCT03614728, NCT03854227, NCT04555473, NCT04676516) for the therapy of hematologic and solid tumors, containing primary and metastatic tumors. Here, PRMT5 is linked to metastatic neoplasm.